Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.
Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - Chief Commercial Officer Mark Jacobson - COO Hunter Murdock - General Counsel Conference Call Participants Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Andrew Tsai - Jefferies Ash Verma - UBS Ram Selvaraju - H.C. Wainwright Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler David Hoang - Deutsche Bank Joon Lee - Truist Securities Cerena Chen - Wells Fargo Jason Gerberry - Bank of America Graig Suvannavejh - Mizuho Securities Yatin Suneja - Guggenheim Partners Myles Minter - William Blair Troy Langford - TD Cowen Ami Fadia - Needham & Company Operator Greetings, and welcome to the Axsome Therapeutics First Quarter 2025 Conference Call and Webcast.
Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.09 per share a year ago.
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol
Axsome's phase III PARADIGM study evaluating solriamfetol in major depressive disorder fails to show a statistically significant change in the primary endpoint.
Why Shares of Axsome Therapeutics Slumped Today
Shares of biopharmaceutical company Axsome Therapeutics (AXSM -6.29%) had declined 6% at 11 a.m. ET today. The slump comes after the company announced the results of a phase 3 trial of solriamfetol (brand name Sunosi) in major depressive disorder (MDD).
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week
Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive. The post Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week appeared first on Investor's Business Daily.
Axsome's depression treatment fails to meet main goal of late-stage study
Axsome Therapeutics said on Tuesday its experimental drug to treat major depressive disorder failed to meet the main goal of a late-stage study.
AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint
Axsome's phase III FOCUS study, evaluating solriamfetol for treating attention deficit hyperactivity disorder, meets its primary and key secondary endpoints.
